AVEO Oncology

Acquired

Advancing Cancer Treatment Innovation

Boston, United States · Founded 2001 · $151.0M raised

Employees
51–200
Founded
2001
Business Model
B2B
Total Funding
$151.0M
Last Round
$151.0M Venture Round
Rounds
1
Acquisition Date
Oct 2022

About

AVEO Oncology is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. Founded in 2001 and headquartered in Boston, Massachusetts, AVEO markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma. In January 2023, AVEO became a wholly owned subsidiary of LG Chem Life Sciences USA, Inc., and continues to operate under the AVEO Oncology name.

Summary

AVEO Oncology is a Biotech company based in Boston, United States, founded in 2001. It has raised $151.0M in total across 1 round. Investors include MPM Capital, Highland Capital Management and Biogen.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

AcquisitionOct 2022
$566.0M

Sign up to see all 6 rounds

Venture Round through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

AVEO Oncology on Indexed.vc
<a href="https://indexed.vc/companies/aveo-oncology"><img src="https://indexed.vc/api/badge/company/aveo-oncology" alt="AVEO Oncology on Indexed.vc" width="260" height="76" /></a>